Prof Geoffrey Dusheiko

Photo

Personal Profile

Name: Geoffrey Dusheiko Email: g.dusheiko@ucl.ac.uk
Title: Prof Tel:
Department: Div of Medicine Fax:
Position: Emeritus Professor Of Medicine Address: , , ,
Research Domain: Global Health, Personalised Medicine Web Page:  

Profile

Research Description


Research Activities

Hepatology

Immunopathogenesis of hepatitis B virus infection

Molecular Virology of Human Hepatitis

Viral infections and innate immune reponses

Education Description

UCL Collaborators

Prof William Rosenberg; Dr Michael Jacobs; Prof Mala Maini; Dr Richard Gilson; Prof Arne Akbar; Prof Mary Collins; Prof Dame Anne Johnson

External Collaborators

Publications

    2012

    • Cacoub P, Bourlière M, Lübbe J, Dupin N, Buggisch P, Dusheiko G, Hézode C, Picard O, Pujol R, Segaert S, Thio B, Roujeau JC (2012). Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.. J Hepatol, 56(2), 455 - 463. doi:10.1016/j.jhep.2011.08.006

    2011

    • Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team (2011). Telaprevir for previously untreated chronic hepatitis C virus infection.. N Engl J Med, 364(25), 2405 - 2416. doi:10.1056/NEJMoa1012912
    • Muir AJ, Poordad FF, McHutchison JG, Shiffman ML, Berg T, Ferenci P, Heathcote EJ, Pawlotsky JM, Zeuzem S, Reesink HW, Dusheiko G, Martin EC, George S, Kauffman RS, Adda N (2011). Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.. Hepatology, 54(5), 1538 - 1546. doi:10.1002/hep.24549

    2009

    • Harrison TJ, Dusheiko GMZ, A J (2009). Hepatitis Viruses. In Zuckerman AJ, Banatvala JE, Schoub BD, Griffiths PD, Mortimer P (Ed.), Principles and Practice of Clinical Virology (pp. 273 - 320). : John Wiley & Sons, Ltd.
    • Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, Lascar RM, Brown D, Gilson RJ, Tedder RJ, Webster G, Dusheiko GM, Jacobs M, Klenerman P, Maini MK (2009). Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology, 137(4), 1289 - 1300. doi:10.1053/j.gastro.2009.06.054
    • van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, Vogel M, Baumgarten A, Chaix ML, Fisher M, Gotz H, Matthews GV, Neifer S, White P, Rawlinson W, Pol S, Rockstroh J, Coutinho R, Dore GJ, Dusheiko GM, Danta M (2009). Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men.. Gastroenterology, 136(5), 1609 - 1617.
    • Maimone S, Calvaruso V, Piequezelo M, Squadrito G, Amaddeo G, Jacobs M, Khanna P, Raimondo G, Dusheiko G (2009). An evaluation of transient elastography in the discrimination of HBeAG-negative disease from inactive hepatitis B carriers. Journal of Viral Hepatitis, 16(11), 769 - 774.
    • Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S, PROVE2 Study Team (2009). Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.. N Engl J Med, 360(18), 1839 - 1850. doi:10.1056/NEJMoa0807650
    • Dusheiko GM, Jacobs MG (2009). Perspectives on the management of chronic hepatitis B and C.. Expert Review of Anti-infective Therapy, 7(3), 243 - 247.

    2008

    • Geretti AM, Madge S, Posner M, Dusheiko G, Jacobs M (2008). Missed opportunities: Undiagnosed HIV infection in patients with viral hepatitis. BMJ (Clinical Research Ed.), 336, 1451 - 1452.
    • Danta M, Semmo N, Fabris P, Brown D, Pybus OG, Sabin CA, Bhagani S, Emery VC, Dusheiko GM, Klenerman P (2008). Impact of HIV on Host-Virus Interactions during Early Hepatitis C Virus Infection. The Journal of Infectious Diseases, 197(11), 1558 - 1566. doi:10.1086/587843
    • Kennedy PTF, Phillips N, Chandrasekhar J, Jacobs R, Jacobs M, Dusheiko G (2008). Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping. Liver International, 28(5), 699 - 704.

    2007

    • McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH, TPL102357 Study Group (2007). Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.. N Engl J Med, 357(22), 2227 - 2236. doi:10.1056/NEJMoa073255
    • Veenstra DL, Sullivan SD, Dusheiko GM, Jacobs M, Aledort JE, Lewis G, Patel KK (2007). Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom. European Journal of Gastroenterology and Hepatology, 19(8), 631 - 638.

    2006

    • Gotto J, Webster GJM, Brown D, Jenkins J, Dusheiko GM, Bertoletti A (2006). The impact of HBV-DNA fluctuations on virus-specific CD8+ T cells in HBeAg+ Chronic Hepatitis B patients treated with a steroid and lamivudine. Journal of Viral Hepatitis, 13(6), 415 - 425.
    • Kennedy PTF, Urbani S, Moses RA, Amadei B, Fisicaro P, Lloyd J, Maini MK, Dusheiko G, Ferrari C, Bertoletti A (2006). The Influence of T Cell Cross-Reactivity on HCVPeptide Specific Human T Cell Response.. Hepatology, 43, 602 - 611.
    • Lurie Y, Rouzier-Panis R, Webster GJ, Dusheiko GM, Laughlin M, Jackson ML, Oren R (2006). Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection.. Clinical Gastroenterology and Hepatology, 3, 610 - 615.

    2005

    • Danta M, Turner JM, Johnstone R, Lascar M, Johnson MA, Dusheiko GM, Williams IG, Gilson RJC, Bhagani S (2005). Early ribavirin improves sustained virological responses in acute HCV infection in HIV-positive individuals..
    • Danta M, Barnes E, Dusheiko (2005). The surveillance and diagnosis of hepatocellular carcinoma.. Journal of Gastroenterology and Hepatology, 17, 491 - 496.
    • Dusheiko G, Bertoletti A (2005). Resistance to lamivudine therapy: is there more than meets the eye?. GUT, 54(1), 9 - 10.
    • Danta M, Turner JM, Johnstone R, Lascar RM, Johnson MA, Dusheiko GM, Williams IG, Gilson RJC, Bhagani S (2005). Use of pegylated interferon-alpha (peg-IFN) with or without ribavirin in the treatment of acute HCV in HIV-positive individuals..
    • Goldin R, Dusheiko GM (2005). The histologist’s role in the diagnosis and management of viral hepatitis B and C..
    • Turner J, Hopkins S, Mahungu T, Johnstone R, Lascar RM, Bhagani S, Dusheiko G, Johnson MA, Williams I, Gilson RJC (2005). Does nadir CD4 count in HIV-HCV co-infected patients predict HCV treatment response to pegylated interferon (p-IFN) and ribavirin (RBV)?.
    • Dusheiko G, Danta M (2005). Can Peg-IFN alpha-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?. Nature Clinical Practice Gastroenterology and Hepatology, 2, 130 - 131.
    • Moore K, Dusheiko G (2005). Opiate abuse and viral replication in hepatitis C. American Journal of Pathology, 167, 1333 - 1340.
    • Moore K, Dusheiko G (2005). Opiate abuse and viral replication in hepatitis C. (Commentary). American Journal of Pathology, 167(5), 1189 - 1191.

    2004

    • Harrison TJ, Dusheiko GM, Zuckerman AJ (2004). Hepatitis viruses. In Zuckerman AJ, Banatvala JE, Griffiths PD, Pattison JR, Schoub BD (Ed.), Principles and Practice of Clinical Virology (pp. 199 - 247). : Wiley and Sons Ltd, Chichester.
    • Sacks SL, Griffiths PD, Corey L, Cohen C, Cunningham A, Dusheiko GM, Self S, Spruance S, Stanberry LR, Wald A, Whitley RJ (2004). HSV shedding.. Antiviral Research, 63(1), S19 - S26.
    • Sacks SL, Griffiths PD, Corey L, Cohen C, Cunningham A, Dusheiko GM, Self S, Spruance S, Stanberry LR, Wald A, Whitley RJ (2004). Lessons from HIV and hepatitis viruses.. Antiviral Research, 63(1), S11 - S18.
    • Danta M, Dusheiko G (2004). Adefovir dipivoxil: review of a novel acyclic nucleoside analogue.. International Journal of Clinical Practice, 58(9), 877 - 886.
    • Whalley SA, Brown D, Webster GJ, Jacobs R, Reignat S, Bertoletti A, Teo CG, Emery V, Dusheiko GM (2004). Evolution of hepatitis B virus during primary infection in humans: transient generation of cytotoxic T-cell mutants.. Gastroenterology, 127(4), 1131 - 1138. doi:10.1053/j.gastro.2004.07.004
    • Sacks SL, Griffiths PD, Corey L, Cohen C, Cunningham A, Dusheiko GM, Self S, Spruance S, Stanberry LR, Wald A, Whitley RJ (2004). Introduction: Is viral shedding a surrogate marker for transmission of genital herpes?. Antiviral Research, 63(1), S3 - S9.
    • Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, Robbins GK, Casson DR, Reiser M, Dusheiko G, Allen TM, Chung RT, Walker BD, Klenerman P (2004). High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection.. Gastroenterology, 127(3), 924 - 936.
    • Barnes E, Ward SM, Kasprowicz VO, Dusheiko G, Klenerman P, Lucas M (2004). Ultra-sensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8+ T cells.. European Journal of Immunology, 34(6), 1570 - 1577.
    • Gotto J, Dusheiko GM (2004). Hepatitis C and treatment with pegylated interferon and ribavirin.. The International Journal of Biochemistry and Cell Biology, 36(10), 1874 - 1877.
    • Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, Williams R, Dusheiko G, Bertoletti A (2004). Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy.. Journal of Virology, 78(11), 5707 - 5719.
    • Fabris P, Brown D, Tositti G, Bozzola L, Giordani MT, Bevilacqua P, de Lalla F, Webster GJ, Dusheiko G (2004). Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C.. Journal of Clinical Virology, 29(3), 160 - 166.
    • Sacks SL, Griffiths PD, Corey L, Cohen C, Cunningham A, Dusheiko GM, Self S, Spruance S, Stanberry LR, Wald A, Whitley RJ (2004). HSV-2 transmission.. Antiviral Research, 63(1), S27 - S35.
    • Barnes E, Salio M, Cerundolo V, Medlin J, Murphy S, Dusheiko G, Klenerman P (2004). Impact of alpha interferon and ribavirin on the function of maturing dendritic cells.. Antimicrobial Agents and Chemotherapy, 49, 3382 - 3389.

    2003

    • Lucas M, Gadola S, Meier U, Young NT, Harcourt G, Kadadimitris A, Coumi N, Brown D, Dusheiko G, Cerundolo V, Klenerman P (2003). Frequency and phenotype of circulating V alpha/V beta 11 double positive natural killer cells during hepatitis C virus infection. Journal of Virology, 77, 2251 - 2257.
    • Barnes E, Mathou N, Qattan I, Brown D, Bloor S, Clarke B, Dhillon A, Dusheiko G (2003). Hepatitis B virus surface gene mutations are often associated with lamivudine resistance mutations in the absence of treatment with hepatitis B immunoglobulin (HBIG).
    • Malacarne F, Webster GJ, Reignat S, Gotto J, Behboudi S, Burroughs AK, Dusheiko GM, Williams R, Bertoletti A (2003). Tracking the source of the hepatitis B virus-specific CD8 T cells during lamivudine treatment. The Journal of Infectious Diseases, 187(4), 679 - 682. doi:10.1086/368369
    • Turner NC, Dusheiko G, Jones A (2003). Hepatitis C and B-cell lymphoma. Annals of Oncology, 14(9), 1341 - 1345.

    2002

    • Dusheiko G (2002). HCV infection should be managed in specialist centres. Gut, 51(5), 625 - 626.
    • Lee C, Dusheiko G (2002). The natural history and antiviral treatment of hepatitis C in haemophilia. Haemophilia, 8(3), 322 - 329.
    • Dusheiko GM (2002). Interferon : biology, pharmacology and therapy for chronic viral hepatitis. In (Ed.), The Cytokine Handbook (pp. 1234 - 1254). : Elsevier Science Ltd.
    • Cochrane A, Searle B, Hardie A, Robertson R, Delahooke T, Cameron S, Tedder RS, Dusheiko GM, De L, X S, P (2002). A genetic analysis of hepatitis C virus transmission between injection drug users. The Journal of Infectious Diseases, 186(9), 1212 - 1221.
    • Barnes E, Harcourt G, Brown D, Lucas M, Phillips R, Dusheiko G, Klenerman P (2002). The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology, 36(3), 743 - 754. doi:10.1053/jhep.2002.35344
    • Reignat S, Webster GJ, Brown D, Ogg GS, King A, Seneviratne SL, Dusheiko G, Williams R, Maini MK, Bertoletti A (2002). Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. Journal of Experimental Medicine, 195(9), 1089 - 1101. doi:10.1084/jem.20011723
    • Sabin CA, Emery VC, Devereux HL, Griffioen A, Bishop J, Dusheiko G, Yee TT, Herrero-Martinez E, Lee CA (2002). Long-term patterns of hepatitis C virus RNA concentrations in a cohort of HIV seronegative men with bleeding disorders. Journal of Medical Virology, 68(1), 68 - 75.

    2001

    • Karadimitris A, Gadola S, Altamirano M, Brown D, Woolfson A, Klenerman P, Chen JL, Koezuka Y, Roberts IAG, Price DA, Dusheiko G, Milstein C, Fersht A, Luzzatto L, Cerundolo V (2001). Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proceedings of the National Academy of Sciences of the United States of America, 98(6), 3294 - 3298.
    • Webster G, Barnes E, Dusheiko G, Franklin I (2001). Protecting travellers from hepatitis A - Vaccine should be used for almost every occasion when prevention is required. BMJ (Clinical Research Ed.), 322(7296), 1194 - 1195.
    • Papatheodoridis GV, Davies S, Dhillon AP, Teixeira R, Goulis J, Davidson B, Rolles K, Dusheiko G, Burroughs AK (2001). The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation, 72(3), 412 - 418.
    • Webster G, Barnes E, Dusheiko G, Franklin I (2001). Protecting travellers from hepatitis A. BMJ (Clinical Research Ed.), 322(7296), 1194 - 1195.
    • Makris M, Baglin T, Dusheiko G, Giangrande PL, Lee CA, Ludlam CA, Preston FE, Watson HG, Wilde JT, Winter M (2001). Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia, 7(4), 339 - 345.
    • Whalley SA, Murray JM, Brown D, Webster GJM, Emery VC, Dusheiko G, Perelson AS (2001). Kinetics of acute hepatitis B virus infection in humans. Journal of Experimental Medicine, 193(7), 847 - 853. doi:10.1084/jem.193.7.847
    • Brechtbuehl K, Whalley SA, Dusheiko GM, Saunders NA (2001). A rapid real-time quantitative polymerase chain reaction for hepatitis B virus. Journal of Virological Methods, 93(1-2), 105 - 113.
    • Whalley SA, Brown D, Teo CG, Dusheiko GM, Saunders NA (2001). Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler. Journal of Clinical Microbiology, 39(4), 1456 - 1459.

    2000

    • Webster G, Barnes E, Burroughs A, Dusheiko G (2000). Organ transplantation and discrimination - Patients with hepatitis B should not be given low priority. BMJ (Clinical Research Ed.), 320(7249), 1600 - 1601.
    • Webster G, Barnes E, Brown D, Dusheiko G (2000). HCV genotypes--role in pathogenesis of disease and response to therapy. Best Practice and Research Clinical Gastroenterology, 14(2), 229 - 240.
    • Webster GJM, Hallett R, Whalley SA, Meltzer M, Balogun K, Brown D, Farrington CP, Sharma S, Hamilton G, Farrow SC, Ramsay ME, Teo CG, Dusheiko GM (2000). Molecular epidemiology of a large outbreak of hepatitis B linked to autohaemotherapy. The Lancet, 356(9227), 379 - 384.
    • Webster G, Rana H, Whalley S, Brown D, Arnlot P, Dusheiko G (2000). Chronological change in natural killer (NK) cell frequency, related to control of viraemia, during the pre-clinical phase of acute hepatitis B. Gut, 46(S2), W56 - .
    • Webster GJM, Rana H, Whalley SA, Brown D, Amlot P, Dusheiko GM (2000). Chronological change in natural killer (NK) cell frequency, during pre-clinical phase of acute hepatitis B infection. Journal of Hepatology, 32(Suppl), 91 - 91.
    • Brown D, Manalakopoulos S, Dusheiko GM (2000). Diagnosis of acute and chronic hepatitis C. In Zuckerman AJ, Thomas HC (Ed.), Viral Hepatitis (pp. 319 - 338). : John Wiley and Sons.
    • Harrison TJ, Dusheiko GM, Zuckerman AJ (2000). Hepatitis Viruses. In Zuckerman AJ, Banatvala JE, Pattison JR (Ed.), Principles and Practice of Clinical Virology (pp. 187 - 233). : Wiley.
    • Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA (2000). The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut, 47(6), 845 - 851.
    • Dusheiko G, Barnes E, Webster G, Whalley S (2000). The science, economics, and effectiveness of combination therapy for hepatitis C. Gut, 47(2), 159 - 161.
    • Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, Brown D, Amlot PL, Williams R, Vergani D, Dusheiko GM, Bertoletti A (2000). Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology, 32(5), 1117 - 1124.
    • Webster G, Whalley S, Barnes E, Dusheiko G (2000). Hepatitis C and G. In O'Grady JG, Lake JR, Howdle P (Ed.), Comprehensive Clinical Hepatology (pp. 13 - 13). : Mosby.
    • Webster GJM, Hallett R, Whalley SA, Meltzer M, Balogun K, Brown D, Farrington CP, Sharma S, Hamilton G, Farrow SC, Ramsay ME, Teo C-G, Dusheiko GM (2000). Molecular epidemiology of a large outbreak of hepatitis B linked to autohaemotherapy. The Lancet, 356(9227), 379 - 384. doi:10.1016/S0140-6736(00)02529-0
    • Webster G, Barnes E, Brown D, Dusheiko G (2000). HCV Genotypes - role in pathogenesis of disease and response to therapy. Best Practice and Research Clinical Gastroenterology, 14(2), 229 - 240.
    • MUTIMER D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, Burroughs A, Hubscher S, Dhillon AP, Rolles K, Elias E (2000). Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation, 70(5), 809 - 815.
    • Lechner F, Sullivan J, Spiegel H, Nixon DF, Ferrari B, Davis A, Borkowsky B, Pollack H, Barnes E, Dusheiko G, Klenerman P (2000). Why do cytotoxic T lymphocytes fail to eliminate hepatitis C virus? Lessons from studies using major histocompatibility complex class I peptide tetramers. Philosophical Transactions of the Royal Society B: Biological Sciences, 355(1400), 1085 - 1092.
    • Webster GJM, Reignat S, Maini MK, Brown D, Whalley SA, Ogg GS, Williams R, Vergani D, Dusheiko GM, Bertoletti A (2000). Dynamics of HBV-specific CD4 and CD8 response during early phase of acute hepatitis B. Journal of Hepatology, 32(Suppl), 90 - .
    • Dusheiko G (2000). Hepatitis C infection: its sequelae and outcomes - State-of-the-Art Workshop, September 24 to 25, 1998. Canadian Association for the Study of the Liver. Canadian Journal of Gastroenterology, 14(Suppl), 49B - 58B.
    • Whalley SA, Murray JM, Brown D, Webster GJM, Emery VC, Dusheiko GM, Perelson AS (2000). The kinetics of acute hepatitis B virus infection in humans. Hepatology, 32(4 Pt 2), 446A - .
    • Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J (2000). Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. New England Journal of Medicine, 343(23), 1673 - 1680.
    • Webster G, Rana H, Whalley S, Brown D, Amlot P, Dusheiko G (2000). Chronological change in natural killer (NK) cell frequency, related to control of viraemia, during the pre-clinical phase of acute hepatitis B. Gut, 46(11), A46 - .
    • Khakoo SI, Ling R, Scott I, Dodi AI, Harrison TJ, Dusheiko GM, Madrigal JA (2000). Cytotoxic T lymphocyte responses and CTL epitope escape mutation in HBsAg, anti-HBe positive individuals. Gut, 47(1), 137 - 143.

    1998

    • Soni PN, Brown D, Saffie R, Savage K, Moore D, Gregoriades G, Dusheiko GM (1998). Biodistribution, stability and antiviral efficacy of liposome-entrapped phosphorothiolate antisense oligonucleotide in ducks for the treatment of chronic duck hepatitis B virus infection. Hepatology, 28(5), 1402 - 1410.
    • Morris A, WEbster ADB, Brown D, Harrison TJ, Dusheiko G (1998). GB Virus C infection in patients with primary antibody deficiency. The Journal of Infectious Diseases, 177(6), 1719 - 1722.
    • Manolakopoulos S, Morris A, Davies S, Brown D, Hajat S, Dusheiko G (1998). Influence of GB virus C viraemia on the clinical, virological and histological features of early hepatitis C-related hepatic disease. Journal of Hepatology, 28(2), 173 - 178.
    • Sabin CA, Devereux H, Kinson Z, Griffioen A, Brown D, Dusheiko G, Lee CA (1998). Effect of coinfection with hepatitis G virus on HIV disease progression in hemophilic men. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 19(5), 546 - 548.
    • Manzini P, Dusheiko GM, Brown D, Khakoo SI, Owen JS (1998). Hepatitis C virus (HCV) tends to associate preferentially with high-density lipoproteins by standard ultracentrifugal fractionation of plasma from patients with chronic HCV infection. Hepatology Research, 11(3), 158 - 165.
    • Morris A, Webster ADB, Brown D, Harrison TJ, Dusheiko G (1998). GB virus C infection in patients with primary antibody deficiency. J Inf Dis 177: 1719-1722.. The Journal of Infectious Diseases, 177, 1719 - 1722.
    • Devereux H, Sabin CA, Kinson Z, Brown D, Griffioen A, Dusheiko GM, Lee CA (1998). Influence of HIV-1 infection on GBV-C infection in multiply infected haemophilic patients. Journal of Medical Virology, 56(4), 316 - 320.

    1997

    • Grellier L, Brown D, Power J, Dusheiko G (1997). Absence of anti-envelope antibodies and clearance of hepatitis c virus in a cohort of Irish women infected in 1977. Journal of Viral Hepatitis, 4(6), 379 - 381.
    • Khakoo SI, Soni PN, Savage K, Brown D, Dhillon AP, Poulter LW, Dusheiko GM (1997). Lymphocyte and macrophage phenotype in chronic hepatitis C infection - Correlation with disease activity. American Journal of Pathology, 150(3), 963 - 970.

    1996

    • Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ (1996). Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine.. Hepatology, 24, 711 - 713.

    1995

    • Soni P, Dusheiko GM, Harrison TJ, Dhillon AP (1995). Genetic diversity of hepatitis C virus: implications for pathogenesis, treatment and prevention. Lancet, 345, 562 - 566.

    1992

    • Xu J, Brown D, Harrison T, Lin Y, Dusheiko G (1992). Absence of Hepatitis B virus Precore Mutants in Patients with Chronic Hepatitis B Responding to Alpha Interferon.. Hepatology, 15, 1002 - 1006.

    1990

    • Harrison TJ, Lin Y, Stamps AC, Dusheiko GM, Zuckerman AJ (1990). Hepatitis B virus-associated hepatocellular carcinoma in African patients.. Cancer Detection and Prevention, 14, 457 - 460.

    • Costelloe SJ, Wassef N, Schulz J, Vaghijiani T, Morris C, Whiting S, Thomas M, Dusheiko G, Jacobs M, Vanderpump MPJ (). Thyroid dysfunction in a UK Hepatitis C population treated with Interferon-α and Ribavirin combination therapy. Clinical Endocrinology, , - .
    • Kajihara M, Montagnese S, Khanna P, Amodio P, Schapira AH, Dusheiko GM, Morgan MY (). Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha2b: a report of two cases. European Journal of Gastroenterology and Hepatology, , - . doi:10.1097/MEG.0b013e32833383e3